Gelonghui, April 16, 丨 Fussen Pharmaceutical (01652.HK) announced that on April 16, 2024, Henan Fusen, an indirect wholly-owned subsidiary of the company (as limited partner A), entered into a limited partnership agreement with the general partner and limited partner B to establish a limited partnership. Henan Fusen's total capital commitment is RMB 85 million, which will be disbursed using the Group's internal resources. The limited partnership will engage in investment business and participate in investing in different potential pharmaceutical-related enterprises or projects.

Qingdao Qiji Electronic Technology Co., Ltd. is a limited company established in China. Limited Partner B is mainly engaged in corporate investment and equity investment. According to the director's full knowledge, knowledge and conviction after making all reasonable inquiries, as of the date of this announcement, Limited Partner B has 100% interest in Zhang Zhifeng.

The Group is mainly engaged in the manufacture and sale of pharmaceuticals in China and Hong Kong. The Group is committed to exploring potential investment opportunities to diversify its business, with the aim of generating revenue and diversifying sources of shareholder returns. The board of directors believes that the establishment of a limited partnership will provide the Group with a good opportunity to prepare for investment in various pharmaceutical-related enterprises or projects, and use the professional investment management knowledge of general partners to bring maximum return on investment to the Group.